Fabrice Lalloué

This study examines how panitumumab affects the proteome of EGFRvIII glioblastoma cells and their extracellular vesicles, showing reduced EGFRvIII on EVs and changes in extracellular matrix proteins.

The paper identifies a proteomic signature in extracellular vesicles from tumor-draining veins of NSCLC patients that may serve as prognostic biomarkers for relapse.

This paper proposes using UHF-dielectrophoresis crossover frequency (EMS) to predict tumor mutational burden (TMB) as a rapid, low-cost alternative to whole exome sequencing.